SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
EDIT

Editas Medicine, Inc. (EDIT)

NASDAQ: EDIT · USD
Healthcare · Biotechnology
$1.64-$0.07 (-4.09%)
 
Market cap
$253M
Insider Score
Analyst consensus
Market Cap$253.12M-33.6%
Revenue (ttm)$49.83M
Net Income-$72.22M
EPS-$0.54
Shares Out154.34M
PE Ration/a
Forward PE-2.26
Dividendn/a
Ex-Dividend Daten/a
Volume2,679,287
Open$1.69
Previous Close$1.71
Day's Range$1.63 - $1.78
52-Week Range$1.63 - $3.94
Beta2.08
AnalystsBuy
Price Target$6.10(+271.95%)
Earnings DateNov 9, 2026

About EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Address
11 Hurley Street, Cambridge, MA, 02141, United States
Market Cap
253 million
Employees
87
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$176.68K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $5.00 (+204.9%)

2 firms rating EDIT in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-4.09%
5 Days
-24.42%
1 Month
-34.14%
6 Months
-40.58%
1 Year
-33.60%

$EDIT stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of EDIT by members of U.S. Congress

Donna ShalalaHouseSale$1.00K – $15.00KJun 4, 2019
Donna ShalalaHousePurchase$1.00K – $15.00KMar 6, 2019

Recently reported changes in EDIT holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by EDIT's directors and management

Net Shares Purchased by Insiders−30k−15k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

EDIT Estimated quarterly lobbying spending

Source: U.S. Senate LDA

EDIT Revenue by Segment

$10.94MTotal
Intellectual property and patent related fees$6.06M55.39%
Sublicense and license fees$4.88M44.61%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New EDIT patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to EDIT from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from EDIT’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
72

News check: Positive gene therapy trial data showing 90% LDL reduction plus revenue beat offset by Q3 loss; concrete clinical progress outweighs financial headwinds.

Recent Insider Activity

Buys
0
Sells
16
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-59.0 since Aug 21
0255075100Aug 21 — Insider Score 59.0Aug 22 — Insider Score 59.0Aug 23 — Insider Score 59.0Aug 24 — Insider Score 59.0Aug 25 — Insider Score 59.0Aug 26 — Insider Score 59.0Aug 27 — Insider Score 60.0Aug 28 — Insider Score 60.0Aug 29 — Insider Score 60.0Aug 30 — Insider Score 60.0Aug 31 — Insider Score 60.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 38.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

WDNAWisdomTree BioRevolution Fund0.66%
QQQSInvesco NASDAQ Future Gen 200 ETF0.44%
MEDXHorizon Kinetics Medical ETF0.30%
GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF0.29%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.24%
GNOMGlobal X - Genomics & Biotechnology ETF0.18%
STSBiShares Factors US Small Blend Style ETF0.15%
XBIState Street SPDR S&P Biotech ETF0.09%
IWCiShares Micro-Cap ETF0.09%
FSEVFidelity Enhanced Small Cap Value ETF0.03%
IBBQInvesco Nasdaq Biotechnology ETF0.02%
IBBiShares Biotechnology ETF0.02%

Weight is the stock’s share of each fund’s holdings.